Your point is the focus of this company:
To circumvent the potential of allogeneic T-cells inducing graft-versus-host disease (GvHD) in recipient patients, the TCR alpha constant (TRAC) gene was inactivated using a proprietary transcription activator-like effector nuclease (TALEN™)-mediated gene editing technology. The CD52 gene was also disrupted using another specific TALEN™ to allow the administration of engineered T-cells following an alemtuzumab-based lymphodepleting therapy.
Google the ASH abstract where it gets even more interesting:
2046 First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL
* Risk mitigation through suicide receptor
Found this article on "The Guardian" from the UK:
"Baby girl is first in the world to be treated with 'designer immune cells'"
....“As this was the first time that the treatment had been used, we didn’t know if or when it would work and so we were over the moon when it did. Her leukaemia was so aggressive that such a response is almost a miracle.” One other patient is already receiving the treatment under the care of a different medical team.
*article was dated 11-5 so I'm expecting expecting good news at the ASH conference as it will be updated in the early December presentation. Nobody can say "cure" yet. However, It does feel like immunotherapy for cancer has taken a major step.
Worth the time to google and read the whole article.
A second patient already confirmed on compassionate use:
"One other patient is already receiving the treatment under the care of a different medical team."
* How do you deny compassionate use to end stage patients that have exhausted options and are nearing death? Off the Shelf means the drug is available and is not going to be unavailable because of the prohibitive cost & production limitations of other T cell therapies currently in trials. I would hate to be the person at Cellectis wanting a controlled trial and fearing the compassionate use leading to use in the wrong patient and the resulting negative headlines from such use. One article quoting Pfizer has mentioned hundreds were currently in that situation.
Great to read The Guardian article on how one baby in dire need got unbelievably good results.
Wall Street and Washington understands how Valiant works and the Mansion people will not lose big money on this one. Jail time for "the grab" on health care dollars? That is taken care of in Healthcare Premiums paid by Joe-6-pack so nobody goes to jail. The books are good and legal. $30B in debt? It's just part of the roll up VRX Wall Street loves.
Pipeline is what WS is selling here and how this company can charge more. Ackman will explain how valuable the VRX drugs are soon, hahaha lol lmao. This one is a game for insiders and can't wait for the public to tire again of the games. No attention means WS is gonna win, always.
Need to pick out my plan options for next year with those higher premiums, WS scum wins again.
Can VRX, Ackman and the rest of Wall Street garbage pay for K-street lobby gang and contribute to this Presidential run? Of course. ((My PREMIUMS have gone up sooooooo much in last 2 years.))
I'm voting for a Trump/Bernie Sanders ticket and hope to see Wall Street $%# in their pants.
Yes gouging is legal. Going forward this company has zero drugs that deserve a premium price. It also has billions in debt it needs gouging pricing to pay off.
Wall Street roll up game putting a lot of money into the hands of a few, again
You are depending on a continued ability gouge on what is the equivalent of a generic portfolio of drugs. Please name one blockbuster drug that doesn't have a reasonable priced substitute. Gouge or die is how Wall Street structured this "roll up".
Still looking at my Insurance Premiums and how this year is another giant leap!!! Wall Street #$%$ and the mansions that have again found a way pick my pockets. Roll ups and debt, look who pays, the consumer.
Price gouging in Health Care is legal and no doubt these guys have been taught well in WallStreet rollups. Versus $30 billion debt and a pipeline that any healthcare professional can tell the generic options are the patients best choice.
If the public is watching (interest rarely last long) the follow up gouging game is toast. If Wall Street gets back in control they will smoke shorts or longs, it's all about how the small investors position themselves.
Regardless this is the kind of $#!+ Wall Street uses to pad their personal affairs. At the expense of Joe-6-pack's Premiums.
But the SEC clawback???? LMAO the SEC #$%$ only supervises Wall Street theft and keeps things orderly. Pearson is set for life. He wouldn't spit on the stock boyz now playing with VRX. It's rigged and the rich just get richer.
These boyz know how do pharmacy roll ups and gouge on the price. Wall Street also taught them how to play so they could run the stock price ever higher via their analysis.... Yes, It's a sack of $#!+ and paid for by our health care benefits and the stupid money that folks invest in via hedges.
Good ole' Merica, land of the get rich quick
The personalized option of Juno is far too expensive and looks like the manufacturing and even delivering options may lead to a greater graft host problem potential. Juno has been a leader in their immune therapy research in human studies to date.
Data that will be very useful in application of UCART19 by Cellectis.
Right from the gouger's mouth. Those rollups where they raised prices on old drugs by 200 to 500 percent are getting bad press in the medical press. Too late and who will trust the boyz at this point?
Is Wall Street positioned to profit from the downside? I'm starting to think so and when it happens I'm sure there are a lot of small guys in the stock that will get hammered, as always.
1. everybody gets to take the fifth amendment
2. price gouging in the health field is rampant (and legal) and nobody in DC wants to see the dominoes starting to fall when they know they are in the food chain
"run amok" you are sooooo right on that
Thanks for the JUNO mention, just read the transcripts that are now linked on the JUNO board. It's open season on "off the shelf" versus autologous. For cancer patients I couldn't imagine a better fight for the future, as in we are seeing the word cure!
$30 billion in debt based on roll up and gouge with 200 to 500 percent markups of acquired drugs. No doubt Pearson wants a nice package and ride into the sunset, he's rich. Math doesn't work for this Wall Street gouge the consumer on health care dollars now that it's in focus.
Sad part is that gouging on health care is legal and nobody goes to jail.
The MAE (material adverse effect) clause is one of the first things arbitrageurs look at in a merger agreement. In the case of the Rite Aid-Walgreens merger, the MAE clause lays out the circumstances under which Walgreens Boots Alliance (WBA) can back out of its merger with Rite Aid (RAD).
Flip side, more sick people to gouge is what Valeant needs. The guy is in a spiral and just getting more attention on a stock that doesn't hold up well under the microscope.
$30 billion in debt that depends on roll ups and gouging on acquired drugs. Is that the business plan? Really?